Multiple Myeloma

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Oncology, Hematology, Hematologic Cancer

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credit / Hematologic Cancer, Oncology

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.0 Credit / Oncology, Hematology, Hematologic Cancer

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

More News

FDA approval indication | Image Credit: Dzmitry - stock.adobe.com

April 6th 2024

FDA Approves Cilta-Cel for Earlier Treatment of RRMM

Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).

April 5th 2024

Ide-Cel Receives Approval for Earlier Treatment for Relapsed, Refractory Multiple Myeloma

Julia Bonavitacola

Idecabtagene vicleucel (ide-cel) was able to triple progression-free survival and reduce the risk of disease progression or death in a phase 3 trial.

Book of cases on multiple myeloma | Image Credit: FelipeCaparros - stock.adobe.com

March 27th 2024

Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma

Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.

Multiple Myeloma Diagram | Image Credit: fancytapis - stock.adobe.com

March 21st 2024

Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment

In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.

March 12th 2024

Dr Imran Khan Addresses Teclistamab’s Groundbreaking Impact and Ongoing Promise

Teclistamab (Tecvayli, Johnson & Johnson), a first-in-class bispecific T-cell–engaging antibody, is approved to treat relapsed/refractory multiple myeloma in the US.

March 4th 2024

Dr Imran Khan Presents a Closer Look at Teclistamab’s Weight-Based Dosing and Patient-Centric Approach

The FDA recently approved the supplemental biologics license application for teclistamab (Tecvayli; Johnson & Johnson) to treat relapsed/refractory multiple myeloma on a biweekly dosing schedule.

February 27th 2024

Dr Imran Khan Discusses Teclistamab’s Expanded Indication for RRMM

Teclistamab (Tecvayli) was first approved for use in patients who have relapsed/refractory multiple myeloma (RRMM) in October 2022, making it a first-in-class bispecific antibody.

enFuse injector | Image: Enable Injections

February 27th 2024

On-Body Delivery System enFuse Saves Time, Improves QOL for Patients

Mary Caffrey

An on-body delivery system approved last fall for paroxysmal nocturnal hemoglobinuria (PNH) has seen rapid uptake and is now being studied for use with isatuximab.

February 23rd 2024

Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma

AJMC Staff

The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.

Multiple myeloma diagnosis | Image credit: ibreakstock - stock.adobe.com

February 15th 2024

Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM

The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.

Doctor is holding diagnosis Multiple myeloma | Image credit: Vitalii Vodolazskyi - stock.adobe.com.jpeg

February 7th 2024

Disability Degree, Home Health Use May Signal Need for Patient Support in MM

Clinical investigators evaluated the impact of home health services on disability status and receipt of treatment among adults 66 years and older with a new diagnosis of multiple myeloma (MM).

multiple myeloma, text on white paper near stethoscope on blue background | Image credit: Svetlana stock.adobe.com.jpeg

January 29th 2024

Best Practices That Target Selinexor Treatment Improve MM-Related Outcomes

Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.

Health Disparities Poster | image credit: Colored Lights - stock.adobe.com

January 26th 2024

Racial Disparities Persist in Multiple Myeloma Treatment

Kyle Munz

A claims-based study analyzing Medicare beneficiaries with multiple myeloma found that racial disparities still impact treatment in this patient population.

January 20th 2024

Overcoming Barriers to Care Equity in Multiple Myeloma

Additional Analyses Needed to Optimize Treatment Efficacy, Sequencing in MM

January 19th 2024

This literature review investigated outcomes related to relapsed/refractory multiple myeloma (MM) among patients 65 years and older.

Managing finances in health care | Image Credit: janews094 - stock.adobe.com

January 13th 2024

New Research Further Supports Use of Financial Navigators in Myeloma Care

Kristie L. Kahl

Patients with multiple myeloma are living longer; therefore, their lifelong treatment expenses can become burdensome.

Doctor with patient in medical office | Image Credit: sebra - stock.adobe.com

January 4th 2024

Understanding the Patient Experience With Belantamab Mafodotin for RRMM

A qualitative interview study gauged patients’ experiences with belantamab mafodotin, which is used to treat relapsed/refractory multiple myeloma (RRMM) following failure on at least 4 prior therapies.

Alissa Visram, MD | Image credit: Ottawa Hospital Research Institute

December 27th 2023

Study Finds Huge Gap Between Clinical Trial Data and Real-World Outcomes in Multiple Myeloma

Mary Caffrey

Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.

December 26th 2023

ICYMI: Highlights From EHA 2023

The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.

L. Andres Sirulnik, MD, PhD | Image credit: Regeneron

December 22nd 2023

LINKER-MM1: Updated Data Show 46% Complete Responses to Linvoseltamab at 11 Months in R/R Multiple Myeloma

Mary Caffrey

Regeneron officials say they are on track to file for FDA approval for the bispecific antibody by the end of 2023.

Multiple myeloma | Image credit: David Litman - stock.adobe.com

December 20th 2023

Older, Younger Patients With MM Show Similar Outcomes With Teclistamab

Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.

December 19th 2023

From CAR T’s “Wait List Mortality” to “Tethering” Bispecific Antibodies, Oncologists Navigate Time-Sensitive Sequencing in Multiple Myeloma

Ryan Flinn

December 19th 2023

Top 5 Most-Read Multiple Myeloma Articles of 2023

Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.

Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com

December 16th 2023

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Silas Inman

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Illustration of T cells - Sebastian - stock.adobe.com

December 15th 2023

Patients With Multiple Myeloma Lack Awareness of CAR T-Cell Therapy, Research Says

Giuliana Grossi

The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.

Cardiovascular system | Image credit: appledesign - stock.adobe.com

December 8th 2023

Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers

Sabrina Serani

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

Blood Cells | Image credit: Катерина Євтехова - stock.adobe.com

November 30th 2023

Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma

A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.

Multiple myeloma blood testing | Image credit: luchschenF - stock.adobe.com

November 29th 2023

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma

Hayley Virgil

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Patient in the hospital | Image credit: Tyler Olson - stock.adobe.com

November 22nd 2023

Minimizing Terms for Toxicity Often Used in Multiple Myeloma Trials, Study Says